Related Experiment Video
Updated: Aug 2, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Empirical, ethical, and political perspectives on the use of methylphenidate
1Folkehelsa National Institute for Public Health, Norway.
Abstract:
The case for methylphenidate (MPH) (Ritalin) rests on claims that Attention Deficit Hyperactivity Disorder (ADHD) is a disorder, that ADHD is biologically rooted, that MPH is effective against ADHD, that nontreatment is developmentally hazardous, and that MPH is a relatively innocuous rather than dangerous treatment. It will be found that the case for MPH rests on the hope that ADHD is a biological disorder and on MPH's short-term suppression of disruptive behavior. The explosion of MPH use on this flimsy evidential base can be explained within a political economy analysis but is difficult to justify ethically. It suggests a disturbing reliance upon drugs to solve problems stemming from a combination of inadequate support for families in modern societies and educational systems pushed to do more with less. Reliance upon a psychoactive medication to make children "ready to learn" is not only unsupported by the evidence, it teaches children incorrect lessons about how to meet the stresses and challenges of life.
Insights
Methylphenidate (MPH) use for Attention Deficit Hyperactivity Disorder (ADHD) lacks strong evidence, relying on short-term behavior control. Over-reliance on MPH may stem from societal issues, not just biological factors.
Area of Science:
- Child psychology
- Neuroscience
- Sociology
Background:
- Attention Deficit Hyperactivity Disorder (ADHD) is often treated with methylphenidate (MPH), commonly known as Ritalin.
- The justification for MPH use is based on claims of ADHD being a biological disorder and MPH's effectiveness.
Purpose of the Study:
- To critically evaluate the evidence supporting the widespread use of methylphenidate for ADHD.
- To explore the ethical and societal implications of relying on MPH for managing childhood behavioral issues.
Main Methods:
- Literature review and critical analysis of existing research on methylphenidate and ADHD.
- Political economy analysis to understand the drivers of MPH prescription rates.
Main Results:
- The case for MPH is based on the assumption of ADHD as a biological disorder and its short-term behavioral effects, not robust evidence.
- MPH's efficacy is primarily linked to short-term suppression of disruptive behavior, with limited long-term data.
Conclusions:
- The extensive use of MPH for ADHD is ethically questionable and lacks strong scientific backing.
- Over-reliance on MPH may mask societal issues like inadequate family support and educational resource limitations.
- Using psychoactive medication to prepare children for learning is unsupported and teaches maladaptive coping mechanisms.
More Related Videos
13:09Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol
Published on: April 1, 2018
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
Related Concept Videos
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS Stimulants: Psychedelic Agents
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.